News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated
